select ad.sno,ad.journal,ad.title,ad.author_names,ad.abstract,ad.abstractlink,j.j_name,vi.* from articles_data ad left join journals j on j.journal=ad.journal left join vol_issues vi on vi.issue_id_en=ad.issue_id where ad.sno_en='48231' and ad.lang_id='5' and j.lang_id='5' and vi.lang_id='5' Diagnostic, Prognostic and Theranostic Biomarkers for Rheuma | 48231
Journal d'immunologie clinique et cellulaire

Journal d'immunologie clinique et cellulaire
Libre accès

ISSN: 2155-9899

Abstrait

Diagnostic, Prognostic and Theranostic Biomarkers for Rheumatoid Arthritis

Cathy M McGeough and Anthony J Bjourson

The identification and adoption of diagnostic and prognostic biomarkers for rheumatoid arthritis has informed and improved the clinical management of this disease. With the advent of biologic treatments such as anti-Tumour Necrosis Factor (anti-TNF) therapy, achieving disease remission has become a realistic endpoint for clinicians. The life-changing efficacy of these therapies however is restricted to the 60-70% of patients who respond. The immune reaction to anti-inflammatory therapy is thought to be influenced by many genes which cumulatively contribute to a threshold for response. There is an inherent clinical need to provide theranostic biomarkers which could determine treatment outcome. The current role of genetic biomarkers in diagnosis, prognosis and predicting response to anti-TNF therapy are discussed.

Clause de non-responsabilité: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été révisé ou vérifié.
Top